
Blau Farmaceutica SA
BOVESPA:BLAU3

Net Margin
Blau Farmaceutica SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
BR |
![]() |
Blau Farmaceutica SA
BOVESPA:BLAU3
|
2.4B BRL |
15%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
322B USD |
7%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
149B USD |
17%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
137.8B USD |
21%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD |
-9%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
113.5B AUD |
18%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
56.4B USD |
32%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42.1B USD |
-11%
|
Blau Farmaceutica SA
Glance View
Blau Farmacêutica SA engages in the manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo and currently employs 1,700 full-time employees. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Blau Farmaceutica SA's most recent financial statements, the company has Net Margin of 15.2%.